Medicine
Erythromycin 500 mg powder for injection
Erythromycin 500 mg powder for injection is a generic prescription medicine for intravenous use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20ºC to 25ºC (68ºF to 77ºF).
Key facts
- Active ingredient (INN)
- Erythromycin
- Brand
- Sold under the generic name
- Strength
- 500 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 10 vials
- Manufacturers
- Piramal Critical CareIndiaArmas Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20ºC to 25ºC (68ºF to 77ºF).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D10AF02 Erythromycin
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 July 2026
- Identifiers
- RxCUI 1668264DailyMed set ID ee345752-0f0c-c69b-e053-2995a90a7dac, ca65a48f-5fe6-4b31-8359-51dbc31f6d4eNDC 66794-251, 72485-701Application ANDA216761
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial in 1 carton / 500 injection, powder, for solution in 1 vial | 66794-251-41 | Piramal Critical CareIndia | 13 August 2026 |
| 10 vial, single-dose in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, single-dose | 72485-701-10 | Armas Pharmaceuticals | 9 July 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 June 1964 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Erythromycin
Clinical summary
Erythromycin is a macrolide antimicrobial indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below, among other approved uses. MedsAcross supplies Erythromycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ErythromycinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ery-Ped prescribing information (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)) · U.S. National Library of Medicine, DailyMed
Need Erythromycin 500 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.